Want to see IN:GUJTHEM full AI Analyst Report?

Gujarat Themis Biosyn Ltd (GUJTHEM) Price & Analysis

1 Followers

GUJTHEM Stock Chart & Stats

₹432.00

Market closed

₹432.00

Day’s Range― - ―

52-Week Range₹225.75 - ₹479.45

Previous CloseN/A

VolumeN/A

Average Volume (3M)24.48K

Market Cap

₹48.43B

Enterprise Value₹26.34B

Total Cash (Recent Filing)₹103.83M

Total Debt (Recent Filing)₹714.92M

Price to Earnings (P/E)83.5

Beta1.95

Next Earnings

Nov 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.18%

Share Statistics

EPS (TTM)2.41

Shares Outstanding130,151,700

10 Day Avg. Volume18,988

30 Day Avg. Volume24,476

Financial Highlights & Ratios

PEG Ratio-11.90

Price to Book (P/B)8.62

Price to Sales (P/S)14.96

P/FCF Ratio-19.41

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)6.9

Revenue Forecast (FY)₹1.88B

Bulls Say, Bears Say

Bulls Say

Strong ProfitabilityHigh operating and net margins indicate that the company retains substantial earnings from its pharmaceutical operations. This profitability provides an internal source of funds for investment and resilience, although maintaining the current margin structure will be important as revenue expands.

Rapid Revenue ExpansionA roughly doubling of revenue demonstrates strong recent scale expansion and can improve operating leverage if the business sustains demand. Continued growth would broaden the earnings base and strengthen the company’s ability to fund development, capacity, and market participation over the coming quarters.

Equity CushionA sizable equity base provides some balance-sheet support against business volatility and reduces the immediate impact of higher borrowings. This cushion can help the company absorb weaker operating periods while preserving more strategic flexibility than a highly debt-dependent capital structure would allow.

Bears Say

Weakening Cash GenerationThe sharp decline in operating cash flow and deeply negative free cash flow show that reported earnings are converting less effectively into cash. If this persists, the company may need external funding for investment or working capital, reducing financial flexibility and increasing execution risk.

Higher LeverageThe rapid rise in leverage increases fixed financial obligations and makes the balance sheet more sensitive to weaker margins or demand. Higher debt can also constrain future capital allocation, because a greater share of cash resources may be required to support financing needs.

Margin CompressionThe substantial gross-margin contraction indicates that revenue growth is not translating proportionately into profit, potentially reflecting cost, mix, or other operating pressures identified in the financial summary. A continued squeeze could weaken earnings quality and limit the benefits of scale.

Gujarat Themis Biosyn Ltd News

Gujarat Themis Biosyn files scrutinizer’s report and voting results for 45th AGM

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) just unveiled an update. Gujarat Themis Biosyn Ltd has reported the...

18d ago

Gujarat Themis Biosyn Revises Filing on 45th AGM, Confirms Dividend and Director Reappointment

An update from Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) is now available. Gujarat Themis Biosyn Ltd has...

19d ago

Gujarat Themis Biosyn Sets 45th AGM to Approve Accounts, Dividend and Board Commission

An update from Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) is now available. Gujarat Themis Biosyn Ltd, a...

2M ago

Gujarat Themis Biosyn Raises Rs 750 Crore via QIP, Expands Equity Base

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) has shared an update. Gujarat Themis Biosyn Ltd has completed a...

2M ago

Gujarat Themis Biosyn Closes QIP, Prices Rs. 354 Equity Issue

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) has provided an announcement. Gujarat Themis Biosyn has closed its qualified...

2M ago

Gujarat Themis Biosyn Board Clears QIP Issue at ₹372.57 Floor Price

The latest announcement is out from Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ). Gujarat Themis Biosyn Ltd has...

2M ago

Gujarat Themis Biosyn Files Audited FY26 Results With Clean Audit Opinion

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) just unveiled an announcement. Gujarat Themis Biosyn Ltd has released its...

2M ago

Gujarat Themis Biosyn Amends Articles to Loosen Share Issuance Valuation Rules

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) has provided an announcement. Gujarat Themis Biosyn Ltd has secured shareholder...

2M ago

Gujarat Themis Biosyn Shareholders Approve Key Amendment to Articles of Association

An announcement from Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) is now available. Gujarat Themis Biosyn Ltd has...

2M ago

Gujarat Themis Biosyn Secures Shareholder Nod for QIP Fundraising Plan

Gujarat Themis Biosyn Ltd ( ($IN:GUJTHEM) ) has shared an announcement. Gujarat Themis Biosyn Ltd has reported the...

2M ago

GUJTHEM FAQ

What was Gujarat Themis Biosyn Ltd’s price range in the past 12 months?

Gujarat Themis Biosyn Ltd lowest stock price was ₹225.75 and its highest was ₹479.45 in the past 12 months.

What is Gujarat Themis Biosyn Ltd’s market cap?

Gujarat Themis Biosyn Ltd’s market cap is ₹48.43B.

When is Gujarat Themis Biosyn Ltd’s upcoming earnings report date?

Gujarat Themis Biosyn Ltd’s upcoming earnings report date is Nov 14, 2026 which is in 26 days.

How were Gujarat Themis Biosyn Ltd’s earnings last quarter?

Gujarat Themis Biosyn Ltd released its earnings results on Aug 07, 2026. The company reported ₹1.016 earnings per share for the quarter.

Is Gujarat Themis Biosyn Ltd overvalued?

According to Wall Street analysts Gujarat Themis Biosyn Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gujarat Themis Biosyn Ltd pay dividends?

Gujarat Themis Biosyn Ltd pays a Annually dividend of ₹0.67 which represents an annual dividend yield of 0.18%. See more information on Gujarat Themis Biosyn Ltd dividends here

What is Gujarat Themis Biosyn Ltd’s EPS estimate?

Gujarat Themis Biosyn Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Gujarat Themis Biosyn Ltd have?

Gujarat Themis Biosyn Ltd has 130,151,700 shares outstanding.

What happened to Gujarat Themis Biosyn Ltd’s price movement after its last earnings report?

Gujarat Themis Biosyn Ltd reported an EPS of ₹1.016 in its last earnings report. Following the earnings report the stock price went down -1.233%.

Which hedge fund is a major shareholder of Gujarat Themis Biosyn Ltd?

Currently, no hedge funds are holding shares in IN:GUJTHEM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.